No Data
Blue Sail Medical (002382.SZ): plans to privately issue no more than 0.5 billion yuan of CSI Enterprise bond Index to professional investors.
On March 10, Gelonghui reported that Blue Sail Medical (002382.SZ) announced that it held the 19th meeting of the sixth Board of Directors and the 13th meeting of the sixth Board of Supervisors on March 9, 2025, where it approved the proposal on the company's eligibility for non-public issuance of corporate bonds, the proposal on the company's plan for non-public issuance of corporate bonds, and the proposal to authorize the Board of Directors and its management to handle all matters related to this non-public issuance of corporate bonds. To expand financing channels and optimize the company's debt structure, and in consideration of the company's actual situation, approval was granted for the issuance directed at professional investors.
Blue Sail Medical (002382.SZ): ShanDong Blue Sail Health Technology has obtained the high-tech enterprise certification.
On March 4th, Gelonghui reported that Blue Sail Medical (002382.SZ) announced that recently, its holding subsidiary ShanDong Blue Sail Health Technology Co., Ltd. (referred to as 'ShanDong Blue Sail Health Technology') received the 'High-tech Enterprise Certificate' jointly issued by the Shandong Provincial Department of Science and Technology, Shandong Provincial Department of Finance, and the State Administration of Taxation Shandong Provincial Tax Service, successfully passing the recognition as a high-tech enterprise.
Blue Sail Medical Co.,Ltd.'s (SZSE:002382) Low P/S No Reason For Excitement
Blue Sail Healthcare: 2024 Annual Results Forecast
Blue Sail Medical (002382.SZ): Expected loss of 0.37 billion yuan to -0.47 billion yuan for the year 2024.
On January 24, Gelonghui reported that Blue Sail Medical (002382.SZ) announced its 2024 annual performance forecast, predicting a Net income loss attributable to shareholders of the listed company of 0.37 billion yuan – 0.47 billion yuan. After deducting non-recurring gains and losses, the Net income loss is expected to be 0.43 billion yuan – 0.53 billion yuan, with a basic EPS loss of 0.37 yuan/share – 0.47 yuan/share. During the reporting period, the sales revenue of the cardiovascular and cerebrovascular division exceeded 1.1 billion yuan, a year-on-year increase of approximately 12%, with gross margin further improved, continuing the trend of annual revenue growth and decreasing sales and management expense ratios since the national collection procurement of coronary Brackets in 2021.
We Think Blue Sail MedicalLtd (SZSE:002382) Has A Fair Chunk Of Debt
Blue Sail MedicalLtd (SZSE:002382) Shareholders Are up 7.2% This Past Week, but Still in the Red Over the Last Three Years
